Cargando…

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer

BACKGROUND: Prostate cancer (PCa), the second most common cancer affecting men worldwide, shows a broad spectrum of biological and clinical behaviour representing the epiphenomenon of an extreme heterogeneity. Androgen deprivation therapy is the mainstay of treatment for advanced forms but after few...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrari, Nicoletta, Granata, Ilaria, Capaia, Matteo, Piccirillo, Marina, Guarracino, Mario Rosario, Venè, Roberta, Brizzolara, Antonella, Petretto, Andrea, Inglese, Elvira, Morini, Martina, Astigiano, Simonetta, Amaro, Adriana Agnese, Boccardo, Francesco, Balbi, Cecilia, Barboro, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721601/ https://www.ncbi.nlm.nih.gov/pubmed/29216878 http://dx.doi.org/10.1186/s12964-017-0206-x

Ejemplares similares

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
por: Capaia, Matteo, et al.
Publicado: (2018)

Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer
por: Benelli, Roberto, et al.
Publicado: (2019)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

Androgen Receptor Activity Is Affected by Both Nuclear Matrix Localization and the Phosphorylation Status of the Heterogeneous Nuclear Ribonucleoprotein K in Anti-Androgen-Treated LNCaP Cells
por: Barboro, Paola, et al.
Publicado: (2013)

Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer
por: Barboro, P, et al.
Publicado: (2009)

Integration of transcriptomic data in a genome-scale metabolic model to investigate the link between obesity and breast cancer
por: Granata, Ilaria, et al.
Publicado: (2019)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

From trash to treasure: detecting unexpected contamination in unmapped NGS data
por: Sangiovanni, Mara, et al.
Publicado: (2019)

Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231
por: Morini, Monica, et al.
Publicado: (2010)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Var2GO: a web-based tool for gene variants selection
por: Granata, Ilaria, et al.
Publicado: (2016)

TumorMet: A repository of tumor metabolic networks derived from context-specific Genome-Scale Metabolic Models
por: Granata, Ilaria, et al.
Publicado: (2022)

Publisher Correction: TumorMet: A repository of tumor metabolic networks derived from context-specific Genome-Scale Metabolic Models
por: Granata, Ilaria, et al.
Publicado: (2022)

An integrated approach to infer cross-talks between intracellular protein transport and signaling pathways
por: Tripathi, Kumar Parijat, et al.
Publicado: (2018)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Differential Proteomic Analysis of Nuclear Matrix in Muscle-Invasive Bladder Cancer: Potential to Improve Diagnosis and Prognosis
por: Barboro, Paola, et al.
Publicado: (2008)

The Role of Nuclear Matrix Proteins Binding to Matrix Attachment Regions (MARs) in Prostate Cancer Cell Differentiation
por: Barboro, Paola, et al.
Publicado: (2012)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer
por: Gunner, Charlotte, et al.
Publicado: (2016)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Lacrimal sac adenocarcinoma managed with androgen deprivation
por: Abramson, David H., et al.
Publicado: (2020)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation modulates the inflammatory response induced by irradiation
por: Wu, Chun-Te, et al.
Publicado: (2009)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

The impact of androgen deprivation on artificial urinary sphincter outcomes
por: Bailey, George C., et al.
Publicado: (2016)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2hsovsing7h2p3b2lbcv0r5rpu